A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Inclusion Criteria: * Unresectable or metastatic advanced solid tumors with no standard therapies, or having progressed on or intolerable to standard therapies. * Advanced solid tumors harboring mutations in KRAS, HRAS or NRAS as determined by laboratory testing, including local laboratory testing. * Measurable disease with at least one lesion amenable to response assessment per RECIST 1.1. * Demonstrate adequate organ function as defined below. All screening laboratories should be performed within 7 days of study treatment initiation. 1）Absolute neutrophil count (ANC) ≥1.2 × 10\^9/L；2）Pla…